Market report on Stem Cell Research in Cardiology emphasizes on the market for stem cells in Cardiology. The study is segmented by Source (Allogenic and Autogenic) and by Type (Bone Marrow Stem Cells, Embryonic Stem Cells, and Other). Estimations and Predictions for 2005-2020 are graphically illustrated by geographic regions encompassing North America, Europe, Asia-Pacific, and Rest of World. Business profiles of 25 major companies are discussed in the report. The text is complemented by 25 exhibits. The report serves as a guide to global market for Stem Cells in Cardiology covering more than 230 companies that are engaged in stem cell R&D, storage, banking, discovery, testing and supply of products and services. Major Contract Research Organizations and Universities serving the industry are also covered in the Corporate Directory section of this report. Compilation of Worldwide Patents and Research related to Stem Cell Research in Cardiology is also provided. Information related to recent product releases, product developments, partnerships, collaborations, mergers and acquisitions, ethical issues, regulatory affairs, and other areas of concern is also covered in the report.

1. RITMIR024: Stem Cell Research in Cardiology – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 1
STEM CELL RESEARCH IN CARDIOLOGY- MARKET SIZE AND OPPORTUNITIES
Scope of the Study
Heart disease has assumed great magnitude as an endemic health problem. Cardiology field has seen
significant efforts in clinical research in the past few years with the development of new drugs and surgical
modalities of therapy as well. However, the mortality rates remain very high. In this context, stem cell
applications in cardiology assume great significance since stem cells have been found to be successfully
used in tissue regeneration. Heart disease, including myocardial infarction and ischemia, can be treated
with the applications of stem cells.
This report emphasizes on the market for stem cells in Cardiology. The study is segmented by Source
(Allogenic and Autogenic) and by Type (Bone Marrow Stem Cells, Embryonic Stem Cells, and Other).
Projections and estimates are graphically illustrated by geographic region encompassing North America,
Europe, Asia-Pacific, and Rest of World. Business profiles of 23 major companies are discussed in the
report. The report serves as a guide to global market for Stem Cell Research in Cardiology covering 229
companies that are engaged in stem cell R&D, storage, banking, discovery, testing and supply of products
and services. Major Contract Research Organizations and Universities serving the industry are also covered
in the Corporate Directory section of this report. Information related to recent product releases, product
developments, partnerships, collaborations, mergers and acquisitions, ethical issues, regulatory affairs, and
other areas of concern is also covered in the report.
Stem Cell Research in Cardiology report is an ideal research tool providing strategic business intelligence to
the corporate sector. This report may help strategists, investors, laboratories, pharmaceutical companies,
contract research organizations, biotechnology companies and drug approval authorities in--
 Gauging Competitive Intelligence
 Identifying Key Growth Areas and Opportunities
 Understanding Geographic Relevance to Product
 Knowing Regional Market Sizes and Growth Opportunities and Restraints
 Keeping Tab on Emerging Technologies
 Equity Analysis
 Tapping New Markets
Analytics and data presented in this report pertain to several parameters such as -
 Global And Regional Market Sizes, Market Shares, Market Trends
 Product (Global And Regional) Market Sizes, Market Shares, Market Trends
 Technology Trends
 Corporate Intelligence
 Key Companies By Sales, Brands, Products
 Consumer Behavioral Patterns
 Other Strategic Business Affecting Data

2. RITMIR024: Stem Cell Research in Cardiology – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 2
Research Methodology
RI Technologies publishes business intelligence reports by going through a cycle of diligent research and
analysis activity. Research is done using both online and offline resources. The study outline of this report is
sketched on the following lines - global market analysis, regional market analysis, product segmentation,
global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape,
technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is
also helpful for doing market evaluations, and estimating the market size for the future.
This report is uniquely researched and the methodology includes:
 Need and Scope of Study
 Product Definitions
 Segmental Analysis
 Regional Analysis
 Exclusive Data Analytics
 Corporate Intelligence
 Feedback
Right from concept to final compilation of this report, both primary and secondary research methods are
applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the
information for authentication of our own findings. Secondary research includes government publications,
investment research reports, web based surveys, website information of both companies and markets, and
other offline resources such as print publications and CDs.
Our compilation of easy to navigate PDF reports are essential value addition resources for leading and
growing companies.

3. RITMIR024: Stem Cell Research in Cardiology – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 3
II. REPORT SYNOPSIS
The Role of Stem Cells in Repairing the Heart
A study was recently conducted wherein it was conclusively proved that stem cell therapies do have a
future role to play in the repairing of the heart.
Human adult stem cells extracted from the bone marrow can produce vascular endothelial cells after their
transplantation is effected into rats.
In one such study using the rat model, the left anterior descending coronary artery was manually
constricted and thus a heart attack was induced. A population of human hematopoietic stem cells was
diligently identified as they obviously cause the production of new blood vessels. This investigation was
similar to the Jackson study.
The stem cells were seen to exhibit the property of plasticity. Now, plasticity in stem cells signifies that the
cells could develop into cell types that they would routinely not tend to become.
These stem cells were then made use of in the formation of new blood vessels in the damaged portions of
the heart. Thereby, proliferation of the preexisting vasculature was encouraged, following the induced
heart attack.
Thus, it is observed that human hematopoietic stem cells have the potential to develop into an array of
tissue types including cardiac musculature given the suitable culture conditions.
The human hematopoietic stem cells were first injected into the bloodstream that entered into the
damaged heart of the rat model. It was noted that these cells could obviate the cessation of the thickened
or hypertrophied myocardial cells. These myocardial cells though damaged were viable. The investigation
also noted the reduction of the progressive development of collagen scars and fibers.
The other groups of rats, which were surgically treated in a controlled condition, that had their left anterior
descending coronary arteries intact, or those, that had their left anterior descending coronary arteries
ligated, were observed. It was found that those control rats that were injected with control cells or saline
did not exhibit any enhancement in their quantity of blood vessels.
The identification of the hematopoietic cells could be performed on the basis of highly specific cell markers.
Eventually, it is possible to differentiate them from cardiomyocyte precursor cells. Thus the cells can be
utilized as they are, or in association with other pharmacological therapies, or myocyte-regeneration designs.
Human embryonic stem cell research is a subject that is attracting immeasurable attention. So much so,
that new findings in the area of cardiomyocyte regeneration are regularly taking place.
Human embryonic stem cells have shown their capability to differentiate into any cell type in the adult
human body and have therefore become a new source population presenting the potential to change into
cardiac-repair cells.
This was pioneered by Itskovitz-Eldor and associates who showed the world that the human embryonic
stem cells can reproducibly differentiate, given appropriate culture, into embryoid bodies comprising of cell
types, which exist in the human body’s three embryonic germ layers.

4. RITMIR024: Stem Cell Research in Cardiology – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 4
Among the different cell types, can be found cells that exhibited the physical appearance of
cardiomyocytes. These cells showed cellular markers that had the properties of heart cells. When they
were carefully studied under a microscope, they were found to demonstrate contractile activity akin to
cardiomyocytes.
At the early part of research activity in this field, the functional and structural attributes of the initial stage
of cardiomyocytes in the cells that develop from the embryoid bodies, were displayed.
Those cells that exhibit contracting activity readily were identified with the use of markers. The markers
were used with antibodies to proteins that exist in the heart tissue. The proteins in the heart tissue are
cardiac troponin, antinaturietic protein, desmin, myosin heavy chain and alpha-actinin.
Upon conducting a genetic analysis of these cells it was noticed that the transcription-factor genes that
were expressed were in conformity with early stage cardiomyocytes. The electrical recordings from these
cells were then carefully observed.
In this study, it was seen that changes did take place in the calcium-ion movement inside the cells. Another
factor namely, the contractile responsiveness to catecholamine hormone stimulation by the cells was
studied.
It was found that these observations were akin to responsiveness, changes and recordings that were made
in early cardiomyocytes, when mammalian development was being investigated into.
Segmentation of Stem Cells in Cardiology
Exhibit 1. Segmentation of Global Stem Cells Market in Cardiology by Source and by Type
Source Stem Cell Type
Allogenic Bone Marrow Stem Cells
Autogenic Embryonic Stem Cells
- *Other
*Cord Blood Cells etc.
© RIT, 2013

5. RITMIR024: Stem Cell Research in Cardiology – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 5
Global Market Analysis
Global Stem Cells in Cardiology market is projected to reach about US$XX.XX billion by 2020 from an
estimated US$XX.XX billion in 2012, growing at a robust compounded annual growth rate (CAGR) of XX.XX%
during the analysis period 2005-2020.
Exhibit 2. Stem Cells in Cardiology - Global Value Market Estimations & Predictions (2005-2020)
in US$ Million
Year Value
2005 XX.XX
2006 XX.XX
2007 XX.XX
2008 XX.XX
2009 XX.XX
2010 XX.XX
2011 XX.XX
2012 XX.XX
2013 XX.XX
2014 XX.XX
2015 XX.XX
2016 XX.XX
2017 XX.XX
2018 XX.XX
2019 XX.XX
2020 XX.XX
CAGR% XX.XX
© RIT Figures, 2013
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Million

6. RITMIR024: Stem Cell Research in Cardiology – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 6
Exhibit 3. List of Major Global Companies
Company Region Website
Aastrom Biosciences, Inc. USA www.aastrom.com
Advanced Cell Technology, Inc. USA www.advancedcell.com
Axordia Limited UK www.axordia.com
Cellartis AB Sweden www.cellartis.com
CellSeed, Inc. Japan www.cellseed.com
CordLife Ltd Australia www.cygenics.com
Gamida Cell Ltd. Israel www.gamida-cell.com
More…
© RIT, 2013

7. RITMIR024: Stem Cell Research in Cardiology – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 7
III. MARKET DYNAMICS
Market Overview
Stem cells give advanced information about how an organism develops from a single cell and how healthy
cells replace damaged cells in adult organisms. This is a very promising area of science and has huge
disease-curing applications. Stem cells are as much part of controversy as they are exciting. They possess
the potential for curing diseases including Alzheimer’s, Diabetes, Huntington’s and Parkinson’s. Stem cell
research itself is controversial as the stem cells are derived from embryos.
Growth of stem cells market worldwide is basically driven by the potential of stem cells for the various
diseases. For example, embryonic stem cells are capable of generating new tissues and organs to replace
the damaged tissues and organs.
Exhibit 4. Stem Cells in Cardiology by Source - Global Value Market Estimations & Predictions (2005 –
2020) for Allogenic and Autogenic Stem Cell Transplantation in US$ Million
Year/Region Allogenic Autogenic Total
2005 XX.XX XX.XX XX.XX
2006 XX.XX XX.XX XX.XX
2007 XX.XX XX.XX XX.XX
2008 XX.XX XX.XX XX.XX
2009 XX.XX XX.XX XX.XX
2010 XX.XX XX.XX XX.XX
2011 XX.XX XX.XX XX.XX
2012 XX.XX XX.XX XX.XX
2013 XX.XX XX.XX XX.XX
2014 XX.XX XX.XX XX.XX
2015 XX.XX XX.XX XX.XX
2016 XX.XX XX.XX XX.XX
2017 XX.XX XX.XX XX.XX
2018 XX.XX XX.XX XX.XX
2019 XX.XX XX.XX XX.XX
2020 XX.XX XX.XX XX.XX
CAGR% XX.XX XX.XX XX.XX
© RIT, 2013
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Million
Allogenic Autogenic

8. RITMIR024: Stem Cell Research in Cardiology – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 8
IV. PRODUCT/TECHNOLOGY RESEARCH
Ever since scientists discovered the great potential that stem cells have in the repair and regeneration of
the body, they have wondered whether stem cells in the heart can generate new tissue to repair damages
such as those caused by a heart attack. Now investigations have revealed a reservoir of stem cells that
could indeed help generate new cells in case of damage to the heart. Experiments with cardiac stem cells
isolated in rats show that they have the ability to repair injured tissue when injected into the heart.
Stem cell therapy is seen as an ideal method for treating cardiac disorders associated with heart muscle
injury. Pre-clinical studies in animal models of acute myocardial infarction appear to be promising for
repairing damaged cardiac muscle and generating new blood vessel formation in the infarcted area. Stem
cell research offers great therapeutic potential and is relevant to basic science researchers, clinicians and
patients.
Exhibit 5. Global Estimates of Number of Deaths Caused by Cardiovascular Diseases (2010)
Disease Number of Deaths
Ischaemic heart disease XX.XX
Cerebrovascular disease XX.XX
Hypertensive heart disease XX.XX
Other Cardiovascular Diseases XX.XX
© RIT Figures, 2013

9. RITMIR024: Stem Cell Research in Cardiology – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 9
STEM CELLS IN CARDIOLOGY - OUTLOOK
The concept of stem cell transplantation to regenerate the myocardium and better the working of the heart
has received a great deal of attention in recent times. Small-scale studies in the pre-clinical and clinical
stages support the use of stem cells in treating heart disease. However similar such studies must be carried
out on a larger-scale to corroborate the findings and prove stem cell therapy as a viable alternative method
of treating patients with heart disease.
Cells in heart’s muscle are not capable of replacing themselves, and therefore the heart does not return to
normal functioning levels once some of these cells are damaged. Other than stem cells therapy and
surgery, there are hardly any effective methods available for treating cardiovascular ailments. This leaves
people with congestive heart failure, heart attack, and congenital heart diseases with little hope to improve
their quality of life. Though transplanting of heart is an effective technique, donors of heart are few in
number. This is where adult stem cell therapy comes in. Adult stem cells are able to coax the existing cells
in the heart’s muscles to produce new heart-muscle cells.
Adult stem cell therapy for treating heart diseases has been examined in medical tests for efficacy as well
as adverse effects. These tests have proved that such stem cell therapy is much better and safer than many
existing procedures for treating cardiovascular diseases. This is the reason adult stem cell therapy is gaining
importance in cardiac stem cell research.
The global market for Stem Cells in Cardiology is projected to reach about US$ XX.XX billion by 2020 at a
CAGR of about XX.XX % from a market of about US$ XX.XX billion in 2012. Adult stem cells market is the
largest tapped market while cord blood and embryonic stem cell markets, though with huge market
potential, are still in infancy stages.
Embryonic stem cells to treat cardiac disorders is the topic of Interest. But, due to its various ethical issues,
is mired in debates all over the world……………………………..
About RI Technologies
RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We
emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly
monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry
based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging
technologies in areas of discovery, design and development.
Research – As Good as the Methodology is!
 Gauging Competitive Intelligence
 Identifying Key Growth Areas and Opportunities
 Understanding Geographic Relevance to Product

10. RITMIR024: Stem Cell Research in Cardiology – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 10
 Knowing Regional Market Sizes and Growth Opportunities and Restraints
 Keeping Tab on Emerging Technologies
 Equity Analysis
 Tapping New Markets
© COPYRIGHT
The copyright and publication rights to all RI Technologies' reports and other products are the property of
the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of
the material without express permission is not allowed. The buyer, under no circumstances, shall license,
resell or repackage, or sell data without prior permission of the company.
DISCLAIMER
RI Technologies sells content in good faith. The company is not liable to the buyer for any implications
arising out of the usage of data for any particular purpose. The company makes no representations or
warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for
data compilation and presentation, the company does not accept any responsibility for findings in the study
which are a cumulative effort of primary and secondary research resources. The studies do not endorse or
promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are
not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage
of the data.